ABSTRACT: The LpxC enzyme in the lipid A biosynthetic pathway is one of the most promising and clinically unexploited antibiotic targets for treatment of multidrug-resistant Gram-negative infections. Progress in medicinal chemistry has led to the discovery of potent LpxC inhibitors with a variety of chemical scaffolds and distinct antibiotic profiles. The vast majority of these compounds, including the nanomolar inhibitors L-161,240 and BB-78485, are highly effective in suppressing the activity of Escherichia coli LpxC (EcLpxC) but not divergent orthologs such as Pseudomonas aeruginosa LpxC (PaLpxC) in vitro. The molecular basis for such promiscuous inhibition of EcLpxC has remained poorly understood. Here, we report the crystal structure of EcLpxC bound to L-161,240, providing the first molecular insight into L-161,240 inhibition. Additionally, structural analysis of the EcLpxC/L-161,240 complex together with the EcLpxC/BB-78485 complex reveals an unexpected backbone flipping of the Insert I βa−βb loop in EcLpxC in comparison with previously reported crystal structures of EcLpxC complexes with L-threonyl-hydroxamate-based broad-spectrum inhibitors. Such a conformational switch, which has only been observed in EcLpxC but not in divergent orthologs such as PaLpxC, results in expansion of the active site of EcLpxC, enabling it to accommodate LpxC inhibitors with a variety of head groups, including compounds containing single (Ror S-enantiomers) or double substitutions at the neighboring Cα atom of the hydroxamate warhead group. These results highlight the importance of understanding inherent conformational plasticity of target proteins in lead optimization.
■ INTRODUCTION
LpxC is an essential zinc-dependent enzyme in Gram-negative bacteria that catalyzes the deacetylation of UDP-3-O-(acyl)-Nacetylglucosamine in the biosynthesis of lipid A, the membrane anchor of lipopolysaccharide. 1 As the major lipid component of the outer monoleaflet of the Gram-negative bacterial outer membrane, lipid A protects bacterial cells from the damage of external agents, such as detergents and antibiotics. The biosynthesis of Kdo 2 -lipid A, the active component of endotoxin, consists of nine steps in Escherichia coli ( Figure  1A) . 1 With the exception of few Gram-negative bacteria, the first step of lipid A biosynthesis catalyzed by LpxA is thermodynamically unfavorable and reversible. 2 Therefore, the second reaction catalyzed by LpxC is generally considered the committed step of lipid A biosynthesis. Since inhibition of LpxC is bactericidal for most Gram-negative bacteria and since LpxC has never been exploited by existing antibiotics, it has become one of the most attractive novel antibiotic targets for treatment of multidrug-resistant Gram-negative infections. Small molecule LpxC inhibitors were initially discovered in the late 1990s using random compound screenings that measured 3 H-galactose uptake in E. coli cells. 10 Lead optimization led to the discovery of L-161,240, a hydroxamate-containing phenyloxazoline compound ( Figure 1B ) that inhibited the growth of E. coli with potency comparable to that of ampicillin. 10 Administration of L-161,240 rescued mice challenged with a lethal dose of E. coli, demonstrating its therapeutic potential. Despite the impressive antibiotic activity of L-161,240 against E. coli in vitro and in vivo, the ineffectiveness of L-161,240 in controlling the growth of Pseudomonas aeruginosa was noted early on. 10 Additional experimentation has shown that the differential antibiotic activities of L-161,240 toward E. coli and P. aeruginosa are due to the greater binding affinity of L-161,240 toward E. coli LpxC (EcLpxC) than toward P. aeruginosa LpxC (PaLpxC) but not due to differences in intrinsic resistance mechanisms of these two bacterial strains, such as membrane permeability or efflux. 11 A similar result was observed for the sulfonamide−hydroxamate compound BB-78485 containing two naphthalene rings ( Figure  1B) . 12 BB-78485 prevented E. coli growth with an antibiotic activity slightly better than that of L-161,240, but it is still ineffective against P. aeruginosa.
Recent medicinal chemistry efforts have led to the discovery of more potent LpxC-targeting antibiotics that are also effective for a wide range of Gram-negative pathogens, including P. aeruginosa. 5,6,9,13−15 In parallel, structural studies of LpxC and its inhibitor-bound complexes have started to unveil the architecture of this essential enzyme and the molecular basis of compound selectivity. 5,15−23 Notably, structural elucidation of different LpxC orthologs in complex with the same diacetylene-based inhibitor LPC-009 has revealed large, inherent conformational differences of the hydrophobic, substrate-binding passage encompassed by Insert II of different LpxC orthologs, which plays a predominant role in accommodating the hydrophobic "tail" of LpxC-targeting antibiotics and in determining their activity profiles. 22 In contrast to many structurally characterized LpxC inhibitors containing a rigid hydrophobic tail inserted into the hydrophobic substrate-binding passage, L-161,240 has a flexible propyl chain and two methoxy groups attached to a phenyloxazoline moiety. Although previous NMR studies have shown that the propyl chain of L-161,240 similarly inserts into the hydrophobic passage as other LpxC-targeting antibiotics, 19 the flexible propyl chain of L-161,240 is unlikely to be affected by conformational variation of the substrate-binding passage accompanied by large changes of the Insert II helix orientation in distinct LpxC orthologs, suggesting that the molecular determinant rendering EcLpxC exquisitely sensitive to the inhibition of L-161,240 arises from structural features other than the Insert II region of EcLpxC.
In order to understand the molecular basis underlying the promiscuous susceptibility of E. coli LpxC to a variety of LpxC inhibitors, including L-161,240 and BB-78485, we determined the structure of EcLpxC in complex with L-161,240 at 2.1 Å resolution. This structure, together with a 1.8 Å resolution structure of EcLpxC bound to BB-78485, reveals a previously unanticipated molecular determinant of the inhibitor specificity structure with EcLpxC/LPC-009. The EcLpxC/L-161,240 complex has an unstructured C-terminal tail, whereas the C-terminus of the EcLpxC/ LPC-009 complex folds into the gap between domains I and II. Insert I, Insert II, and the C-terminus (residues 288−300, modeled) are highlighted in orange, blue, and red, respectively. Inhibitors are shown with a stick model, and the active site zinc ion is shown with a space-filling model. and sheds structural insights into further development of LpxCtargeting antibiotics.
■ RESULTS AND DISCUSSION
Structure of EcLpxC in complex with L-161,240. The crystal structure of EcLpxC in complex with L-161,240 was determined at 2.1 Å resolution using molecular replacement with the previously reported EcLpxC/LPC-009 complex structure as the search model. 22 Because of disorder at the Cterminus, the last six amino acids of EcLpxC were not modeled. The EcLpxC/L-161,240 complex crystals were grown in significantly different crystallization conditions from previously reported EcLpxC−inhibitor crystals, and they belong to the trigonal R3 2 space group rather than the hexagonal P6 1 space group observed for other EcLpxC structures. 15, 22 In addition, previously reported crystals contained a single molecule in each asymmetric unit, whereas two EcLpxC/L-161,240 complexes arrange as a parallel homodimer to form the crystallographic asymmetric unit (Figure 2A ). Since EcLpxC behaves as a monomer in solution, this crystallographic dimer is unrelated to its biological function.
The EcLpxC/L-161,240 complex shows a similar overall topology as previously reported Aquifex aeolicus LpxC structures. 16−18 EcLpxC consists of two domains with a β−α−α−β sandwich fold, and each domain contains a unique insert region: Insert I of Domain I and Insert II of Domain II. Interestingly, the EcLpxC/L-161,240 complex has a fully extended C-terminal tail that interacts with the neighboring protomer in the unit cell in a domain-swapped fashion (Supplemental Figure S1 , Supporting Information). Such an extended tail conformation differs from other EcLpxC− inhibitor structures, 15, 22 in which the C-terminus folds into the gap between Domains I and II ( Figure 2B ). Given the solution NMR observation of a flexible and unprotected Cterminal tail of the EcLpxC/L-161,240 complex, which allows for its recognition and degradation by the FtsH protease, 24 the domain swapped loop conformation of the C-terminal tail in the EcLpxC/L-161,240 complex likely reflects a crystal packing artifact.
The molecular scaffold of L-161,240 can be divided into three distinct regions: a hydroxamate group, an oxazoline ring, and a phenyl ring substituted with two methoxy groups and a propyl chain ( Figure 1B) . Each of these three regions exhibits unique interactions with LpxC to form a tight-binding complex. The hydroxamate headgroup of L-161,240, a primary affinity determinant shared by many potent LpxC inhibitors, participates in coordination of the catalytic zinc with its two oxygen atoms ( Figure 3A ). The hydroxamate oxygen atoms of L-161,240 form a typical penta-coordination together with three conserved LpxC residues, H79, H238, and D242; however, the coordination geometry in the EcLpxC/L-161,240 complex is vastly different from other LpxC/ hydroxamate inhibitor complexes, which coordinate the catalytic zinc with an approximate square-pyramidal geometry. Instead, L-161,240 chelates the catalytic zinc ion in a trigonalbipyramidal geometry ( Figure 3B ), with H79, H238, and the hydroxyl oxygen of the hydroxamate group forming the central plane and with D242 and the carbonyl oxygen of the hydroxamate group forming two apical vertices. Compared with other LpxC−inhibitor complexes, such as the EcLpxC/ LPC-009 complex, 22 the PaLpxC/BB-78485 complex, 21 and the AaLpxC/TU-514 complex, 25 the plane formed by the hydroxamate atoms in the EcLpxC/L-161,240 complex rotates ∼25°around the hydroxamate hydroxyl oxygen. The nitrogen atom of the hydroxamate group of L-161,240 does not appear to form direct hydrogen bonds with the side chains of the catalytically important residues E78 and H265 as in other LpxC/inhibitor complexes ( Figure 3A ). The hydroxamate carbonyl oxygen, however, still forms a hydrogen bond with the hydroxyl group of the conserved T191 side chain.
The second region of L-161,240, the oxazoline group, is connected to the hydroxamate group by a chiral carbon. The vast majority of known LpxC inhibitors can be categorized loosely as amino acid derivatives ( Figure 1B) , with the substituted nitrogen group and the hydroxamate group being R1 and R2 and the Cα substitutions being R3 and R3′. In L-161,240, the nitrogen and alkoxy sides of the bulky cyclic moiety stem from the R1 and R3′ positions of the chiral Cα carbon, respectively, rendering L-161, 240 as an R-enantiomer, as opposed to the S-enantiomer inhibitors, such as L-threoninebased CHIR-090 and LPC-009 containing a proton at R3′ and the threonine side chain at R3 ( Figure 1B) . While the threonyl moiety of the S-enantiomer compounds CHIR-090 or LPC-009 forms extensive interactions with highly conserved residues on the Insert II side of the LpxC active site, the oxazoline moiety of L-161,240, due to its R-configuration at the Cα-position next to the hydroxamate group, tilts toward the βa−βb loop of Insert I on the opposite side of the active site of EcLpxC, with its nitrogen atom forming a hydrogen bond with the backbone carbonyl group of L62 to hold the oxazoline ring ( Figure 3A) .
The third moiety of L-161,240, the substituted phenyl moiety, interacts extensively with the hydrophobic substratebinding passage. The phenyl ring is located at the "mouth" of the hydrophobic passage, and its propyl group inserts into the hydrophobic passage ( Figure 3A ,C), with the terminal methyl group of the propyl chain reaching to the close proximity of the backbone amides of G210 and S211 of the Insert II at the exit of the hydrophobic passage, a configuration consistent with prior solution NMR studies of the EcLpxC/L-161,240 complex. 19 Although the penetration of the L-161,240 is shallower than that of CHIR-090 or LPC-009, the EcLpxC/L-161,240 complex shows an equivalent opening of the external exit of the hydrophobic passage ( Figure 3C ). Within the active site, the phenyl ring of L-161,240 is supported by favorable van der Waals (vdW) contacts with the methyl groups of L62. Additionally, water-mediated hydrogen bonds are formed between the two methoxy groups of L-161,240 and the side chain of D197 and may serve to fixate the orientation of the Insert II helix ( Figure 3A) .
Backbone Flipping of Insert I Residues in EcLpxC. Despite the overall structural similarity of the EcLpxC/L-161,240 complex with other EcLpxC/inhibitor complexes, detailed structural comparison of the EcLpxC/L-161,240 and EcLpxC/LPC-009 (PDB entry 3P3G) complexes has revealed an unexpected conformational change of Insert I ( Figure 3D ). In particular, we note that the βa−βb loop of Insert I in the EcLpxC/L-161,240 complex undergoes complete backbone flipping for L62 and C63 located in the loop connecting βa and βb strands of Insert I. As a result of such backbone flipping, the side chain of C63 rotates by almost 180°relative to its orientation in the EcLpxC/LPC-009 complex, pulling away from the hydrophobic passage to avoid a potential steric clash with the oxazoline moiety of L-161,240. In contrast, in the LPC-009 complex that contains a proton at R3′ instead of a bulky substituent, the side chain of C63 flips down and points toward the hydrophobic passage of EcLpxC. Such a notable conformational change of the backbone flipping and side chain rotation in the EcLpxC/L-161,240 complex causes the βa−βb loop to shift away from the active site by ∼2.0 Å, creating a more spacious active site cavity than that observed for the EcLpxC/LPC-009 complex to accommodate the R-stereospecific substitution at the Cα position next to the hydroxamate group of L-161,240.
Having shown that the EcLpxC/LPC-009 and EcLpxC/L-161,240 complexes have relatively minor global conformational differences, but very distinct configurations of the βa−βb loop of Insert I, we suspected that the ability of the βa−βb loop of EcLpxC to adopt two distinct conformations directly underlies its extraordinary ability to accommodate a variety of diverse inhibitors, including BB-78485, which also is an R-enantiomer at the Cα position next to the hydroxamate group, with one naphthalene ring connected through a sulfonamide group to the R1 position of the chiral carbon and the other naphthalene ring connected to the R3′ position ( Figure 1B) . To test this hypothesis, we additionally determined the crystal structure of the EcLpxC/BB-78485 complex, which reveals an overall similar topology for LpxC and an identical binding mode of BB-78485 as the previously reported PaLpxC/BB-78485 structure, 21 with both naphthalene groups pointing toward the hydrophobic passage ( Figure 4A) . Strikingly, in the EcLpxC/BB-78485 complex, we observed the same Insert I conformation found in the EcLpxC/L-161,240 complex, where the βa−βb loop of Insert I flips out to create a more spacious active site to accommodate BB-78485 ( Figure 4B ). The magnitude of the Insert I conformational rearrangement induced by BB-78485 binding is even more pronounced than that induced by L-161,240, due to the presence of the bulkier naphthalene-sulfonamide moiety. Thus, the conformational plasticity of the βa−βb loop of Insert I of EcLpxC may be a unique structural feature that enables EcLpxC to accommodate inhibitors with divergent chemical scaffolds in the active site. In support of this notion, PaLpxC appears to have a more rigid βa−βb loop in Insert I, which does not undergo any significant conformational change upon BB-78485 binding, resulting in severe penalty of the binding energy. Accordingly, PaLpxC is inhibited poorly by BB-78485. Its MIC value is at least 16-fold higher against an E. coli− PaLpxC knock-in strain than against WT E. coli (Table 1) , indicating a similar reduction of binding affinity of BB-78485 toward PaLpxC compared with EcLpxC. Additionally, binding of BB-78485 significantly increases the isotropic temperature factor of the βa−βb loop of Insert I in the PaLpxC/BB-78485 complex, 21 whereas the corresponding region has a much smaller B-factor in the PaLpxC/LPC-009 complex 22 and in the EcLpxC/BB-78485 complex (this work) ( Figure 4C ), suggesting that although the unflipped Insert I conformation of PaLpxC can easily accommodate S-enantiomer compounds such as L-threonine-based LPC-009, 22 such a rigid conformation is far less capable of accommodating the bulky naphthalene moiety of BB-78485.
In order to further investigate the role of the βa−βb loop in inhibitor selectivity, we attempted to generate chimeric LpxCs in which the βa−βb loop was swapped between EcLpxC and PaLpxC and vice versa. Unfortunately, expression of the PaLpxC chimera with the EcLpxC βa−βb loop (58-RDTMLCTC-65) formed an inclusion body, whereas the EcLpxC chimera with the PaLpxC βa−βb loop (58-GETTMSTT-65) is unstable in solution and does not allow for reliable measurements for inhibitor binding.
Conformational Flexibility of Insert I of E. coli LpxC Accommodates Cα Doubly Substituted LpxC Inhibitors. One limitation of hydromaxate compounds is their relatively high plasma clearance rates due to the metabolic turnover of the hydroxamate group through glucuronide conjugation and aldehyde oxidase-mediated metabolism. 26 Substituting the hydroxamate group with the carboxylate group significantly improves the half-life of parent compounds, but such a substitution invariably results in a complete loss of antibiotic activity of LpxC inhibitors. 5, 27 Another approach to suppress the metabolic turnover of the hydroxamate group is through introduction of sterically hindered functional groups (e.g., an additional methyl group) at the neighboring Cα position of the hydroxamate group. 28 Although such substitution generates vdW clashes in our structural model of the EcLpxC/LPC-009 complex, the observation that Insert I of EcLpxC is capable of undergoing backbone flipping to generate an expanded active site to accommodate R-enantiomer compounds L-161,240 and BB-78485 suggests that with a flipped Insert I, EcLpxC may be able to tolerate inhibitors containing such modification. To test this hypothesis, we synthesized a derivative of LPC-009 and LPC-011, which contains a Cα-methyl substituted threonylhydroxamate headgroup and an amino-substituted biphenyl diacetylene scaffold. Indeed, such a methyl substituted compound (LPC-138) is well tolerated by EcLpxC, with a MIC value of ∼0.24 μg/mL, which is similar to that of CHIR-090 and slightly worse than LPC-009 and LPC-011 (∼5−8-fold; Table 1 ). In contrast, although CHIR-090, LPC-009, and LPC-011 display broad-spectrum antibiotic activities against a variety of Gram-negative bacteria, the Cα-methyl substituted compound LPC-138 has become a specific antibiotic similar to L-161,240 and BB-78485 (Table 1) , and it is effective only for E. coli and closely related Gram-negative bacteria, whose LpxC enzymes share a high degree of sequence identity with EcLpxC and presumably a flexible Insert I capable of conformational flipping to interact with Cα doubly substituted inhibitors (Table 1) .
In order to verify this predicted mode of interaction of LPC-138 with LpxC, we carried out structural analysis of EcLpxC in complex with LPC-138 ( Figure 5 ). As expected, LPC-138 binds in the hydrophobic passage, with an overall binding mode very similar to that of LPC-009 reported previously. 22 The introduction of the Cα-methyl substitution however causes rotation of the neighboring amide bond and the proximal phenyl ring to avoid internal steric clashes, and these changes generate a flipped Insert I conformation of EcLpxC that coexists with an unflipped Insert I conformation. The coexistence of two conformations of the EcLpxC Insert I is consistent with the smaller spatial footprint of the Cα-methyl group and its neighboring amide group compared with the Rsubstituted oxazoline ring in L-161,240 and the naphthalene group of BB-78485, and such an observation reinforces the notion of conformational flexibility of the Insert I loop of E. coli LpxC.
Implication for Inhibitor Design. Since the discovery of L-161,240, LpxC inhibitors with a variety of chemical scaffolds have been reported, each with distinct antibiotic profiles. A vast majority of these compounds efficiently inhibit the growth of E. coli and are selective inhibitors for EcLpxC, but not for PaLpxC. How EcLpxC binds these compounds, including compounds with two distinct stereospecific configurations at the Cα-position of the hydroxamate group has remained a mystery. Here, we shed light on this conundrum by determining the structures of EcLpxC in complex with L-161,240, BB-78485, and a newly designed compound LPC-138. Together, these structures reveal the conformational flexibility of the Insert I loop of EcLpxC as the molecular basis underlying the extraordinary susceptibility of EcLpxC to diverse inhibitors. While LpxC orthologs with a rigid Insert I region are only capable of interacting with S-enantiomer inhibitors such as CHIR-090, LpxC orthologs with a flexible Insert I region, represented by EcLpxC, are able to alter the size and the shape of the active site in response to inhibitor binding by adopting different conformations of Insert I. Such conformational flexibility allows EcLpxC to accommodate a variety of LpxC inhibitors with distinct scaffolds, including compounds that contain R-substituted bulky moieties at the Cα-position next to the hydroxamate group and compounds with double substitutions at the Cα position.
Our study suggests that the successful design of broadspectrum LpxC inhibitors will require navigating differences in conformations and flexibilities of distinct LpxC orthologs. The previously reported diacetylene-based inhibitor LPC-009 is an excellent example of a compound whose elastic scaffold allows it to overcome structural variations in the Insert II hydrophobic passage of distinct LpxC orthologs and is essential for its broadspectrum antibiotic activity. 22 In this study, we reveal another key motif, the βa−βb loop of Insert I, that confers resistance to L-161,240 and BB-78485, suggesting that more flexible inhibitors would be necessary to overcome the conformational heterogeneity of both Insert I and Insert II of LpxC. Conversely, subtle changes of broad-spectrum inhibitors such as LPC-009 and LPC-011 that exploit the unique conformational plasticity of the βa−βb loop in EcLpxC and closely related orthologs can provide a strategy to design highly potent inhibitors for use against a specific set of Gram-negative pathogens, such as Shigella, Salmonella, Yersinia, Vibrio, and Klebsiella.
Another important insight of this work is the trigonalbipyramidal geometry of the catalytic zinc coordination in the EcLpxC/L-161,240 complex. Because square pyramidal geometry has been observed for all other hydroxamate-containing inhibitors, this zinc coordination state has generally been regarded as a primary restraint for structure-based design of LpxC inhibitors. However, it is well-known that many zincdependent enzymes utilize the Berry pseudorotation process, the isomerization between two penta-coordination geometries, for transition-state stabilization in catalysis. Thus, our observation of a trigonal-bipyramidal zinc coordination may provide important insights into LpxC catalysis and new metal constraints for computational design of novel inhibitors. Furthermore, this alternative zinc coordination may affect the overall position of an inhibitor in the active site and enable the incorporation of new scaffolds into LpxC-targeting antibiotics.
■ METHODS Chemical Synthesis. CHIR-090, BB-78485, L-161,240, LPC-009, and LPC-011 were synthesized as described. 12, 13, 15, 29 Synthesis of LPC-138 (Scheme 1) commenced from methyl (2R,3S,7R,7aS)-7-methoxy-2,3,7,7a-tetramethyl-5-oxotetrahydro-2H-oxazolo [4,3-b ]-oxazole-3-carboxylate (1), which was generated as reported. hydroxamate 2 31 in 81% yield. Acidic hydrolysis of the substrate 2 afforded amino acid hydroxamate 3 in 55% yield. Reaction of the amino acid derivative 3 with pentafluorophenyl (PFP) ester 5, which was prepared from corresponding carboxylic acid 4, 15 provided amide 6 in 81% yield. Upon subsequent deprotection of the benzyl group in the substrate 6, using BCl 3 , the final compound LPC-138 was obtained in 56% yield.
Crystallization and X-ray Data Collection. Protein samples were prepared as described previously. 15, 22 For the L-161,240 complex, purified EcLpxC was diluted to a final concentration of 6 mg mL −1 , and a 4-fold molar excess of L-161,240 dissolved in DMSO was added to the diluted protein. The protein and inhibitor were incubated on ice for 1 h to obtain a homogeneous sample before setting up crystallization screening. EcLpxC/L-161,240 complex crystals were produced with the sitting drop vapor diffusion method at 4°C, in drops containing 2 μL of the EcLpxC/L-161,240 mixture and 1 μL of well solution consisting of 0.1 M sodium citrate tribasic dehydrate, pH 5.6, 20% 2-propanol, 20% w/v PEG 4000, and 10 mM DTT. Diffraction data were collected at the Southeast Regional Collaborative Access Team (SER-CAT) 22-BM beamline at the Advanced Photon Source (APS) at Argonne National Laboratory.
For the BB-78485 complex, EcLpxC protein was diluted to a final concentration of 10 mg mL −1 , mixed with 4-fold molar excess of BB-78485 dissolved in DMSO, and incubated on ice for 1 h. The complex crystals were obtained using the hanging drop vapor diffusion method at 4°C, with a reservoir solution containing 3.6 M sodium formate (Hampton Research), 10% glycerol, and 10 mM DTT. Two microliters of the complex sample was mixed with an equal amount of reservoir solution prior to equilibration. Diffraction data were collected in-house at 100 K using a Rigaku MicroMax-007 HF rotating anode generator and R-Axis IV++ detector.
For the LPC-138 complex, initial screening failed to yield any crystals. After reviewing the previously published crystallization structure of the EcLpxC/LPC-009, 22 we were able to identify an impurity molecule that contains a threonyl-hydroxamate group coupled to a phenyl-acetylene group (4-ethynyl-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide) lying at the interface of two EcLpxC molecules. Such a compound does not bind EcLpxC with an appreciable affinity based on ITC studies (data now shown). Inclusion of such a molecule (1.2 mM) similarly stabilizes the crystal packing of the EcLpxC/LPC-138 complex, and we were able to obtain diffraction quality crystals by mixing 10 mg mL −1 protein solution with a 4-fold molar excess of LPC-138 dissolved in DMSO. The EcLpxC/LPC-138 crystals were obtained with the sitting drop vapor diffusion method at 4°C, in drops containing 1.2 μL of the complex sample and 0.9 μL of well solution consisting of 0.1 M HEPES, pH 7.5, 1.7 M lithium sulfate, and 16 mM DTT. The crystals were cryoprotected with perfluoropolyether (PFO-X175/08) before flash-freezing. Data set of the EcLpxC/LPC-138 complex cocrystal was collected at the SER-CAT 22-ID beamline at the Advanced Photon Source (APS) at Argonne National Laboratory. All the X-ray diffraction data were processed with HKL2000. 32 Model Building and Refinement. Molecular replacement with the program PHASER 33 was used to obtain initial phases for LpxCinhibitor structures using the EcLpxC/LPC-009 complex (PDB entry 3P3E) as the search model. Water molecules were added using PHENIX and verified with COOT. 34, 35 An additional molecule (ligand or additive) was found at the packing interface of EcLpxC molecules in the EcLpxC/BB-78485 complex and in the EcLpxC/LPC-138 a Values in parentheses are for highest-resolution shell. b 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst.
complex, which likely stabilizes the crystal packing of the complex. The statistics for these structures are shown in Table 2 .
MIC Tests. MIC tests were carried out as described previously using a modified NCCLS protocol, which is adapted to 96-well plates and LB media in the presence of 5% DMSO. 22, 36 Briefly, 100 μL of various concentrations of compounds were prepared on a standard 96-well plate (Corning Costar 3596, flat bottomed with lid, polystyrene wells), in 2-fold dilution series with a range of 0.0005 to 100 μg/mL. Bacterial cells, grown to OD 600 = 0.6, were diluted 1:100 into LB medium, and 100 μL of the diluted cells was added into each well and incubated at 37°C for 22 h. After the incubation, 50 μL of 1 mg mL −1
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide solution (MTT) was added and incubated at 37°C for another 3 h. The MIC was determined as the lowest concentration of an antibiotic that prevented color change (yellow to black).
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